Using artificial intelligence (AI) to examine echocardiograms (ECGs) can identify patients at risk of developing atrial fibrillation (AF), as well as accurately predicting one-year all-cause mortality, data presented at the American Heart Association Scientific Sessions (AHA 2019; 16-18 November,...
Major infection in patients with cardiac implantable electronic devices (CIED) is associated with a threefold risk of mortality at one year, and impaired quality of life through six months, according to data presented by Bruce Wilkoff (Cleveland Clinic, Cleveland,...
Biosense Webster, a Division of Johnson & Johnson, has reaffirmed its commitment to tackling atrial fibrillation (AF) by launching two major initiatives to coincide with Global AF Aware Week, 18–24 November 2019. A press release from the company outlines...
Children and teens with cardiac arrhythmias are more likely to have depression, anxiety and attention deficit hyperactivity disorder (ADHD) compared with those of similar ages without chronic medical conditions or with certain select chronic childhood diseases, according to preliminary...
Correvio announced the presentation of new data from the SPECTRUM study evaluating Brinavess (vernakalant hydrochloride, IV), an antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), at the American Heart Association (AHA) 2019 Annual Meeting (16–18...
Final results from the Apple Heart study demonstrate a low probability of receiving an irregular pulse notification. It also found that 34% of those who received notification of an irregular pulse were diagnosed with atrial fibrillation (AF) on subsequent...
Monday 18 November marks the start of Global AF Aware Week 2019, launched by the AF Association. The annual awareness week is dedicated to raising awareness of atrial fibrillation (AF), through the association’s Detect, Protect, Correct, Perfect campaign. A press...
A joint press release from Bristol Myers Squibb and Pfizer has highlighted the findings of an artificial intelligence (AI)-based machine learning (ML) technique that has been shown in a test database to exhibit greater predictive performance than other currently...
A wrist-based optical blood pressure monitor has the potential to replace cuff monitoring systems for ambulatory blood pressure, suggests a study in the journal Blood Pressure Monitoring. A press release from Aktiia, the Swiss-based company manufacturing the device, states...
Medtronic has announced results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study. A press release from the company says that the study shows that an investigational set of algorithms in the Micra Transcatheter Pacing System...
Highlights: ESC guidelines on supraventricular tachycardias underline the pivotal role of catheter ablation therapy Study suggests increased use of DOACs in AF leads to lower healthcare costs Profile: Pedro Brugada Cynthia James discusses how she and colleagues developed a...
Left atrial appendage closure (LAAC) via implanted device was associated with a decreased risk of admission for stroke, compared with the expected risk without anticoagulation therapy, according to a study published in the Journal of the American Medical Association...
Stereotaxis and ADAS 3D Medical have announced that the first patients have been treated with the integration of ADAS 3D’s advanced preoperative substrate mapping and Stereotaxis’ robotic magnetic navigation technologies. ADAS 3D helps identify possible sources of dangerous irregular heartbeats...
CardioFocus has announced that the first patients in France have been treated in the University Public Hospital of Nancy with the HeartLight endoscopic ablation system as part of a distribution partnership with MicroPort CRM France. To date, more than 7,000...
Cardiva Medical has said that results from the AMBULATE pivotal study demonstrate the safety and efficacy of its VASCADE MVP venous vascular closure system compared to manual compression. The results were published online in the Journal of the American...
Early mortality following atrial fibrillation (AF) ablation affects nearly one in 200 patients, with the majority of deaths occurring during 30-day readmission, an analysis of a nationally representative US cohort has revealed. Writing in the Journal of the American...
Bardy Diagnostics announced that it was selected as winner of the ‘Remote Monitoring in Arrhythmias’ Technology and Innovation Pitch Session held as part of the digital health programme at the European Society of Cardiology (ESC) Congress 2019 (31 August–4...
The use of defibrillation testing (DFT) when inserting an implantable cardioverter defibrillator (ICD) declined significantly in US hospitals between 2010 and 2015; during the same time period there was an increase in institutional variability in performing DFT that was...
Different strategies are needed to address the continuing lack of diversity in the US cardiology workforce, say the authors of a cross-sectional study which found that numbers of underrepresented minority (URM) individuals and women remain proportionately lower, and that...
Daiichi Sankyo has announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients, mostly elderly, treated with edoxaban (Lixiana). The results from the ongoing Global ETNA-AF registry, were presented at the Great Wall International...
iRhythm Technologies has launched its Zio service in the UK to support the identification and clinical diagnoses of cardiac arrhythmias such as atrial fibrillation (AF). To aid in the diagnosis of the condition, iRhythm has developed Zio, a wearable...
The US Food and Drug Administration (FDA) has approved Farxiga (dapaglifozin, AstraZeneca) to reduce the risk of hospitalisation for heart failure in adults with type 2 diabetes and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. The...
Acutus Medical and Innovative Health have announced a partnership in electrophysiology that they say will offer advanced technology to improve patient outcomes in a cost-efficient manner. A joint press release from the two venture-backed companies says that they will...
Douglas Drachman has been selected as the next vice chair of the American College of Cardiology’s Annual Scientific Session. Drachman will serve as vice chair for two years, at ACC ‘21 and ACC ‘22, and then as chair for...
Researchers have used cardiac magnetic resonance (CMR) imaging for the first time to demonstrate the mechanistic improvements in cardiac contractility consequent to cardiac resynchronisation therapy (CRT), as well as the relative safety of the approach. Presenting the findings this...
Osita Okafor (Aston University, Birmingham, UK) presented an oral abstract this week at the Heart Rhythm Congress (HRC 2019; 6–9 October, Birmingham, UK) that demonstrated that post-implantation changes in QRS area, derived from vectorcardiography (VCG), are superior to QRS...
The use of a Stochastic Trajectory Analysis of Ranked signals (STAR) mapping approach consistently identified early sites of activation (ESA) in patients with persistent atrial fibrillation (AF), and the ablation response was compatible with these ESA being driver sites....
Hugh Calkins (Baltimore, USA) tells BLearning Cardio at Venice Arrhythmias 2019 (3–5 October; Venice, Italy) that the 2019 HRS consensus document is extremely important because it defines a new disease and that this broad group of patients need careful evaluation and detailed management. Electrophysiologists must read...
Antonio Raviele (Venice, Italy), the president of Venice Arrhythmias 2019 (3–5 October; Venice, Italy), talks to BLearning Cardio about some of the current challenges in atrial fibrillation (AF) management, which he notes include lifestyle modification and risk factor modification and the risk to...
Orchestra BioMed, a biomedical innovation company, announced results from its MODERATO II double-blind, randomised study of BackBeat Cardiac Neuromodulation Therapy (CNT). In a press release, the company states that it demonstrated statistically significant and clinically meaningful reductions in systolic...
Data from an interim analysis of heart failure patients treated in the CorCinch FMR study show, a press release reports, that the AccuCinch ventricular repair system (Ancora Heart) is associated with a favourable safety profile, with 97% freedom from...
A prespecified analysis of data from the AUGUSTUS study, released at late-breaking session at the Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019; 25–29 September, San Francisco, USA) and published online in Circulation, indicate that anticoagulation with apixaban and a...
A new study from New Zealand, just published in the New Zealand Medical Journal, has revealed that automated external defibrillators (AEDs) in the community are, alarmingly, not “actually that accessible”. The study found there were only three devices in Hamilton that...
Primary prevention of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy (ARVC) remains challenging; Cynthia James explains how she and colleagues developed a model for selecting patients suitable for placement of implantable cardioverter-defibrillators (ICDs), and what further refinements are needed. Arrhythmogenic...
Disclaimer: This advertorial is sponsored by Abbott The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ (SE), is a unique mapping catheter that, when used with the EnSite Precision™ Cardiac Mapping System, allows bipole recording of waveforms in both the parallel...
Disclaimer: Advertorial sponsored by Abbott Launched in May 2019 by Abbott, the next-generation Confirm Rx™ insertable cardiac monitor (ICM) has both the CE Mark in Europe and Food and Drug Administration clearance in the United States. The Confirm Rx ICM...
The US Food and Drug Administration (FDA) has granted Fast Track designation for the development of dapagliflozin (Farixga, AstraZeneca) to reduce the risk of cardiovascular death or the worsening of heart failure in adults with heart failure with reduced...
Stereotaxis has appointed Kimberly Peery as chief financial officer (CFO), effective from 1 October 2019. Martin Stammer, who has served as CFO since 2013, has accepted a position as the CFO of a large professional services firm headquartered in...
  EBR Systems has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its WiSE cardiac resynchronisation therapy (CRT) for the treatment of heart failure. The WiSE (wireless stimulation endocardially) CRT system is designed...
Jenny Bjerre outlines the results of a study presented at the European Society of Cardiology Congress (ESC 2019; 31 August–4 September, Paris, France) which examined the information on driving restrictions provided to patients following implantable cardioverter defibrillator (ICD) therapy,...
Personalised education delivered in a home setting significantly reduces hospitalisations in patients with atrial fibrillation (AF). This was among the findings of the HELP-AF (Home-based education and learning programme) study, which was presented by Prashanthan Sanders (University of Adelaide...
A study that compared the use of maximum-fixed energy and low-escalating energy shocks for cardioversion in patients with atrial fibrillation (AF) found that maximum-fixed shocks were significantly more effective at cardioverting AF. No differences were found in any safety...
AtriCure has entered into a definitive agreement to acquire SentreHEART, which developed the LARIAT device for left atrial appendage closure in patients with atrial fibrillation. A press release reports that the transaction consideration consists of an upfront payment of...
Virtual patient care is creating exciting learning opportunities for interventional cardiologists. Atman P. Shah considers how training through gaming can deliver a state-of-the-art profession. Recently, I was between patients, with a few minutes to spare. I opened an app on...
RHYTHM AI has announced the closure of a £2.15 million seed financing round. The round was led by an affiliate of Rinkelberg Capital, a private wealth management firm based in London, and was supported by investment from founders. The...
iRhythm Technologies has announced a collaboration with Verily to develop solutions aimed at improving the screening, diagnosis, and management of patients with atrial fibrillation (AF). A press release from iRhythm says that the collaboration brings together its expertise in...
Omar Ishrak, Medtronic’s chairman and CEO is to retire on 26 April 2020, following the end of the company’s current fiscal year. Also, the Medtronic Board of Directors has announced key leadership appointments as part of its multi-year, leadership...
  New data from the Swedish Heart Failure Registry indicate the use of an implantable cardioverter defibrillator (ICD) in patients with heart failure with reduced ejection fraction (HFrEF) is associated with a significant reduction in all-cause mortality at both one...
Results from the Atrial fibrillation progression trial (ATTEST) were presented on 31 August at the European Society of Cardiology (ESC) Congress 2019 in Paris, France. ATTEST is the first randomised controlled trial to directly compare the effectiveness of ablation...
At the 2019 European Society of Cardiology (ESC) Congress (31 August–4 September, Paris, France), Pavel Osmancik (Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic) presented the results of PRAGUE-17. These showed that left atrial appendage closure (LAAC)...
A four-year Italian study of oral anticoagulant (OAC) use in patients with atrial fibrillation (AF) has shown that as prescription rates increased healthcare costs per patient decreased. Prescription rates for antiplatelet agents fell during the same time period. Other...
The European Society of Cardiology (ESC) unveiled guidelines for treatment of supraventricular tachycardia (SVT) on the opening day of its Congress (ESC 2019; 31 August–4 September, Paris, France). Simultaneously published online in the European Heart Journal, the document provides...
A retrospective analysis of data from the Framingham Heart Study has determined that, although heavy smokers have a significantly decreased risk of cardiovascular disease (CVD) within five years after smoking cessation in comparison to current smokers, their risk remains...
Applying artificial intelligence (AI) to a standard electrocardiogram (ECG) may be used to determine physiological age, according to a study published in Circulation: Arrhythmia and Electrophysiology. Zachi Attia (Mayo Clinic, Rochester, USA) et al found that an AI algorithm...
William W Pinsky and Mandeep R Mehra explain to Cardiovascular News how international medical graduates contribute to both their adopted country and their country of origin, providing benefits for all. It should come as no surprise that international medical graduates...
Philips is showcasing its latest cardiac care innovations at the ESC Congress 2019 (European Society of Cardiology; 31 August–4 September, Paris, France). At the congress, Philips is showcasing Release 5.0 of its EPIQ CVx cardiology platform for the first...
AtriCure has received US Food and Drug Administration (FDA) 510(k) clearance of additional labelling claims for AtriClip LAA management devices, including changing the indication from occlusion of the LAA to exclusion, and also adding electrical isolation as a labelling...
ZOLL Medical has confirmed that it has completed the previously announced acquisition of Cardiac Science Corporation, a leading provider of automated external defibrillators (AEDs), related services, and accessories. "We are excited about the alignment of our two companies and our combined ability...
The first patient has been enrolled in the CorCinch EU study, which is a European multicentre clinical evaluation of the AccuCinch ventricular repair system (Ancora Heart) as a treatment for patients with reduced ejection fraction systolic heart failure. This...
AtriCure has revealed that it has entered into a definitive agreement to acquire SentreHeart. Under the terms of the acquisition agreement, the transaction consideration consists of an upfront payment of approximately US$40 million in cash and AtriCure common stock,...
New results support the feasibility of an entirely extracardiac pacing method in a heterogeneous patient population, using a minimally invasive, parasternal delivery approach, with adequate sensing and thresholds suited for temporary pacing. The study, authored by Anne-Floor BE Quast,...
By Prof Dr Christoph T Starck, FEHRA                         This advertorial was sponsored by Cook Medical We report the case of a 74-year old-male patient with a cutaneous device perforation due...
Biotronik has announced the publication of the SENSE trial results in the Journal of Cardiovascular Electrophysiology, proving Biotronik's DX system is equivalent to dual-chamber implantable cardioverter defibrillators (ICDs) in detecting atrial high-rate episodes (AHREs). Trial data also demonstrate that...
SentreHeart recently announced it has successfully completed nine first-in-human procedures utilising the Lariat with EpiRail at John Paul II hospital in Krakow, Poland. The Lariat with EpiRail is an epicardial-only, percutaneous approach to complete and permanent closure of the...
An artificial intelligence (AI) model has been found to identify patients with intermittent atrial fibrillation even when performed during normal rhythm using a quick and non-invasive 10 second test, compared to current tests which can take weeks to years....
A study of 174 hospitals in Australia and New Zealand, published recently in the Annals of Internal Medicine, shows that the quality of care people receive may account for the wide variation in the rate of complications after having...
Roderick Tung (Chicago, USA) talks to BLearning Cardio about the results of the His-SYNC trial which he presented at HRS 2019. The His-SYNC trial set out to compare the effectiveness of His bundle pacing compared with biventricular pacing as first-line therapy in...
Acutus Medical has announced the publication of the UNCOVER AF study in Circulation: Arrhythmia and Electrophysiology. The study demonstrated 73% single-procedure freedom from atrial fibrillation (AF) at 12 months with the use of Acutus' AcQMap advanced cardiac imaging and...
In a large, real-world population of cardiac resynchronisation therapy recipients followed by remote monitoring, use of the adaptive cardiac resynchronisation therapy biventricular and left ventricular algorithm compared to standard biventricular pacing was associated with a “significantly reduced risk” of...
The American College of Cardiology/American Heart Association (ACC/AHA) recently published new primary prevention of heart disease guidelines. The guidelines focus on traditional recommendations for managing conditions like atrial fibrillation (AFib), irregular heartbeat, and atherosclerosis that put someone at increased...
Biotronik has announced FDA clearance of the BioMonitor III injectable cardiac monitor (ICM). BioMonitor III is designed to document suspected arrhythmia or unexplained syncope with increased clarity, enabling fast diagnosis and appropriate treatment. This news follows the recent European...
A new method of evaluating irregular heartbeats outperformed the approach that is currently used widely in stroke units to detect instances of atrial fibrillation. The technology, called electrocardiomatrix, goes further than standard cardiac telemetry by examining large amounts of telemetry...
  Medtronic has announced plans for a global registry of its HeartWare HVAD System, following the release of two-year outcomes from the LATERAL clinical trial. The HVAD System is a left ventricular assist device (LVAD) that helps increase the amount...
A pooled analysis of five-year data from the PROTECT AF and PREVAIL trials has shown left atrial appendage closure (LAAC) to be cost‐effective, and to save costs in comparison to warfarin or non-vitamin K antagonist oral anticoagulant (NOAC) therapy. Published...
Christoph Starck (Berlin, Germany) and Saumya Sharma (Houston, USA) discuss the benefits of using rotational transvenous lead extraction (TLE) tools. Starck and Sharma note that the safety profile of the devices is “compelling” and that they are used by...
Using insertable cardiac monitors (ICMs) to identify atrial fibrillation (AF) in a population at high risk for stroke guides both immediate and long-term patient management. The findings were from an analysis of REVEAL-AF, and were published in the American Journal...
The American Heart Association has awarded research grants of more than US$14 million to four scientific teams to create a new research network focused on cardiac arrhythmias and sudden cardiac arrest. The teams, based at Northwestern University, the University of...
A company providing what a press release calls “next-generation electrophysiology technology solutions” has announced that it now has US$170m financing. The press release reports that this includes a US$100 million Series D equity financing and a US$70 million credit...
After receiving the CE mark, Biotronik has launched its next-generation injectable cardiac monitor (ICM)—BioMonitor III—onto the European market. A press release reports that the novel device is designed to help patients with irregular heart rhythms by documenting suspected arrhythmia...
The Liverpool Centre for Cardiovascular Science, an alliance between academia and the NHS, was established to advance cardiovascular and stroke research and innovation locally, nationally, and internationally. The director of the centre, Professor Gregory YH Lip, Price-Evans chair of...
Zoll Medical, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, has acquired TherOx—a company on improving treatment of acute myocardial infarction and markets systems to deliver super saturated oxygen (SSO2) therapy. A press release reports...
A Philips press release reports both the EPIQ CVx and EPIQ CVxi now include automated applications for 2D assessment of the heart, as well as robust 3D right ventricle volume and ejection fraction measurements—with the aim of making accurate...
Data presented at Heart Rhythm 2019 (8–11 May, San Francisco, USA) and published in JACC: Clinical Electrophysiology indicates that the QDOT MICRO (Biosense Webster), designed to facilitate high power-short duration radiofrequency ablation, demonstrated safety and efficacy in achieving pulmonary...
A company providing what a press release calls “next-generation electrophysiology technology solutions” has announced that it now has US$170m financing. The press release reports that this includes a US$100 million Series D equity financing and a US$70 million credit...
Primary implantable cardioverter-defibrillator (ICD) implantation may have an incremental benefit for patients who have ischaemic cardiomyopathy without heart failure symptoms. The findings, published in Heart Rhythm, indicate that these patients have a higher risk of appropriate ICD therapy compared...
The one-year bleeding risk for patients with atrial fibrillation (AF) who undergo transcatheter aortic valve implantation (TAVI) is the same whether they are receiving vitamin K antagonist therapy or a non-vitamin K antagonist (NOAC). However, the risk of all-cause...
The HeartLight Endoscopic Ablation System is now offered at more than 100 hospitals worldwide. CardioFocus highlighted the expanded availability of its catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI) in a press release. According to the press...
Zoll Medical, which manufactures medical devices and related software solutions, has signed a definitive agreement to purchase Cardiac Science, a provider of automated external defibrillators (AEDs), related services, and accessories. In a press release from Zoll announcing the deal, Elijah...
  Stereotaxis has announced the first graduating class from its Robotic Electrophysiology Fellows Programme. A press release from the company explains that the programme is designed to enhance the traditional electrophysiology fellowship by facilitating mastery of robotic magnetic navigation, fostering a...
Cardiologists can help to reduce the threat of nuclear war and move “the hands of the Doomsday Clock back from the midnight hour”, according to an opinion piece published in Circulation. James E Muller (Brigham and Women’s Hospital, Boston,...
The Carnation Ambulatory Monitor (Bardy Diagnostics) has received the “Best New Diagnostic Technology” award in the 2019 MedTech Breakthrough Awards programme. In a press release, Bardy Diagnostics says the device achieved the award for its innovative P-wave centric ambulatory...
The Heart Rhythm Society has published a white paper looking at the consequences of oral anticoagulants for managing stroke risk in atrial fibrillation which suggests that success with left atrial appendage closure (LAAC) device implantation may represent a “turning...
Asymptomatic heart failure patients are likely to benefit from prophylactic implantable cardioverter defibrillator (ICD) treatment, irrespective of cardiomyopathy aetiology, according to the findings from a study that assessed appropriate device therapy and mortality in New York Heart Association (NYHA)...
The American College of Cardiology (ACC) has announced the appointment of Ranna Parekh as its first director of diversity and inclusion. Parekh will work with the ACC Task Force on Diversity and Inclusion and other societies and organisations to...
  Medtronic has announced US Food and Drug Administration (FDA) clearance and commercial launch for the SelectSite C304-HIS deflectable catheter system for use in procedures involving His-bundle pacing (HBP). According to a press release, the SelectSite C304-HIS deflectable catheter system...
Valentina Kutyifa (Rochester, USA) discusses the late-breaking study findings looking at data from the family of MADIT (Multicenter Automatic Defibrillator) trials. Kutyifa told Cardiac Rhythm News that the key takeaway from the analysis of the trials’ data was that cardiac...
Ante Anic (Split, Croatia) discusses the first in-human trial (CRYO-FIM) looking at a novel cryoballoon ablation system for pulmonary vein isolation at HRS 2019 (8–11 May) in San Francisco, USA. Anic outlines how the cryoballoon ablation system works and notes...
Johannes Brachmann (Coburg, Germany) speaks to Cardiac Rhythm News at HRS 2019 about the REAFFIRM trial, which compared the use of rotor ablation versus conventional ablation when treating patients with persistent atrial fibrillation. Brachmann outlines the key findings of the...
According to a press release, Boston Scientific has initiated the OPTION trial to compare safety and effectiveness of the next-generation Watchman FLX left atrial appendage closure platform to first-line oral anticoagulants (OAC)—including direct oral anticoagulants (DOAC) and warfarin—for stroke...
The Emblem subcutaneous implantable defibrillator system (S-ICD; Boston Scientific) demonstrated a high conversion efficacy and low adverse event rate. Data from the UNTOUCHED trial on the first 30 days after implantation of the device were simultaneously released at a...
CardioFocus recently announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3 system for the treatment of AFib. The results were presented during the Heart Rhythm Society's 40th Annual Scientific Sessions (8–10 May, San Francisco,...
A trial evaluating Parasym’s neurostimulation technology shows that an ear-clip-like device can help reduce atrial fibrillation burden. The results were presented at the Heart Rhythm Society’s 40th Annual Scientific Sessions (HRS; 8–11 May) held in San Francisco, USA. The TREAT...
Implantable cardiac devices are underused, with widespread gender and race treatment disparities, and low referral rates to electrophysiologists, according to the findings from three studies presented at the Heart Rhythm Society’s 40th Annual Scientific Sessions (HRS 2019; 8–11 May,...
Data presented at EuroPCR today indicates that renal denervation with the Symplicity system (Medtronic) is associated with a reduction in subclinical atrial fibrillation in high-risk patients with hypertension over a median follow-up of two years. In the study, 80 patients...
Device-related thrombus (DRT) following left atrial appendage occlusion (LAAO) with the Amplatzer Amulet device (Abbott) was “infrequently” observed according to a report published in JACC: Cardiovascular Interventions (JACC: CI). Writing in JACC: CI, Adel Aminian (Centre Hospitalier Universitaire de Charleroi,...
Highlights: CABANA finds reduced AF and better quality of life after ablation but no reduction in mortality ELIMINATE-AF shows low thromboembolic and bleeding events with edoxaban Profile: Charles Antzelevitch Victor Sanfins discusses his clinical experience with Biotronik's Acticor/Rivacor ICDs...
A stochastic vector-based approach to mapping and ablation of atrial fibrillation (AF) can be used to determine early sites of activation and to guide the ablation of AF drivers. Findings from targeted ablation in persistent AF using the stochastic...
The US Food and Drug Administration (FDA) has granted approval to Medtronic for the Attain Stability Quad MRI SureScan left heart lead. It is the only active-fixation left heart lead, and is designed for precise lead placement and stability,...
This advertorial has been sponsored by BIOTRONIK Dr. Victor Sanfins is a cardiologist at Hospital da Senkora da Oliveira in Guimarães, Portugal, and a specialist in implantable electronic cardiac devices. Speaking to Cardiac Rhythm News at the 2019 annual congress...
Biotronik recently announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices. Leading electrophysiologists throughout the USA are now treating patients with the new implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy defibrillators...
Acutus Medical recently announced CE mark approval for AcQMap contact mapping software, offering expanded functionality that provides physicians with more options to inform individualised patient therapy. The company also announced FDA clearance of its second generation AcQMap platform. All...
In a late-breaking session at the European Heart Rhythm Association annual congress (EHRA; 17–19 March, Lisbon, Portugal), Jason Andrade of Vancouver, Canada presented the results of the CIRCA-DOSE study, a randomised clinical trial designed to evaluate the safety and...

Charles Antzelevitch

Charles Antzelevitch is professor and executive director of the cardiovascular research program at the Lankenau Institute for Medical Research in Pennsylvania, and professor of medicine and pharmacology and experimental therapeutics at Sidney Kimmel Medical College in Philadelphia, Pennsylvania. He...
The KardiaMobile device from AliveCor has received two additional Food and Drug Administration (FDA) 510(k)-cleared indications for arrhythmias that are not atrial fibrillation—for bradycardia, a resting heart rate of between 40–50 beats per minute, and for tachycardia, a heart...
An analysis on the impact of stroke severity in patients receiving the HeartWare HVAD system (Medtronic) as destination therapy shows that targeted blood pressure management helped reduce serious strokes. The HVAD system is a left ventricular assist device (LVAD)...
FEops has received CE mark approval for its FEops HEARTguide. According to a press release, FEops HEARTguide is a one-in-its-kind procedure planning environment for structural heart interventions that provides physicians unique insights to evaluate device sizing and positioning preoperatively...
The Luminize (Boston Scientific) radiofrequency balloon catheter is safe and effective at 30 days in the treatment of atrial fibrillation, data from the AF-FICIENT I study has shown. Amin Al-Ahmad (Texas Cardiac Arrhythmia Institute, Austin, TX, USA) presented the...
Phased radiofrequency (RF) ablation using the PVAC GOLD catheter for pulmonary vein isolation in paroxysmal and persistent atrial fibrillation (AF) has demonstrated good outcomes for quality of life and 12-month efficacy. Results from the multicentre GOLD-AF registry were presented...
An app on a smart watch can be used to detect atrial fibrillation, providing a boost for the role of digital technology in healthcare. Mintu Turakhia and Marco Perez (Stanford University School of Medicine, CA, USA) presented the findings from...
  CardioFocus has announced the European CE Mark approval for its HeartLight X3 endoscopic ablation system, used in the treatment of atrial fibrillation. The HeartLight X3 system is a third generation technology which performs pulmonary vein isolation (PVI) using laser energy...
Researchers have identified a combination of serum biomarkers that is independently associated with higher prevalence of atrial fibrillation, and with increased incidence and recurrence of atrial fibrillation following ablation. The findings from Susana Ravassa (University of Navarra, and Navarra...
Uninterrupted anticoagulation with edoxaban (Lixiana, Daiichi Sankyo) resulted in low rates of thromboembolic and bleeding events in patients with atrial fibrillation undergoing catheter ablation, according to data from ELIMINATE AF, presented at a late breaking session at the European...
Sudden cardiac arrest remains a major cause of death among young people. Babken Asatryan outlines his research into the genetic basis of the disease, and discusses the clinical usefulness that his findings on genetic mutations could have for the...
As part of a session on novel mapping and ablation technologies of atrial fibrillation (AF) at the recent AF Symposium in Boston, USA (24–26 January), Andrea Natale gave a presentation on high power short duration ablation of AF, focusing...
Catheter ablation for atrial fibrillation leads to a reduction in atrial fibrillation, better quality of life and lower hospitalisations than medical therapy, but does not significantly reduce the risk of death, disabling stroke, serious bleeding, or cardiac arrest the...
Several treatment options are available for atrial fibrillation (AF), including pharmacological rate or rhythm control, and catheter or surgical ablation. However, consensus as to the most effective treatment remains elusive. The Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial...
Bruce Wilkoff (Cleveland Clinic, Cleveland, USA) presented results of the worldwide randomised antibiotic envelope infection prevention trial (WRAP-IT) to reduce CIED infection at the 2019 annual meeting of the European Heart Rhythm Association (EHRA; 17–19 March, Lisbon, Portugal). The...
Boston Scientific announced data from the AF-FICIENT I study during a late-breaking clinical trial session at the 2019 European Heart Rhythm Association annual congress (EHRA; 17–19 March, Lisbon, Portugal). The data demonstrated positive safety and efficacy results with the...
In a late-breaking session at the 2019 European Heart Rhythm Association annual congress (EHRA; 17–19 March, Lisbon, Portugal), Jason Guy Andrade of Vancouver, Canada presented results of the CIRCA-DOSE study, a randomised clinical trial designed to evaluate the safety...
Boston Scientific announced it has received CE mark and initiated a limited market release of the next generation Watchman FLX left atrial appendage closure (LAAC) device in Europe. Patients with AF are five times more likely to suffer a...
Biotronik today announced the European market release of the world’s smallest implantable cardioverter-defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) that are approved for 3 Tesla (3T) full-body MRI scans.1 According to a press release, the Acticor and Rivacor...
In a late breaking session at the 2019 AF Symposium in Boston, USA (24–26 January), it was announced that a dipole density (DD) mapping and ultrasound imaging system to identify non-pulmonary vein (PV) targets in persistent atrial fibrillation (AF)...
The commissioner of the US Food and Drug Administration (FDA), Scott Gottlieb, has unexpectedly resigned after serving just shy of two years in the post. Gottlieb announced his intention to stand down in a letter to Alex Azar II, the...
Highlights: Mapping dynamic patterns during atrial fibrillation can produce higher success rates More than 40% of patients with atrial fibrillation attend the emergency department inappropriately Profile: David Callans Eric Prystowsky, Peter Kowey and Munveer Thind debate the CABANA trial ...
Biotronik, the University of Newcastle (Callaghan, Australia) and the Hunter New England Local Health District (HNE LHD) have partnered to shape a heart failure care model. To date, the Australian government and Biotronik have invested in the partnership. According to a press release,...
It was recently announced that Biosense Webster has enrolled and treated the first patient in its US Investigational Device Exemption (IDE) study, which evaluates the company's QDot Micro radiofrequency (RF) ablation catheter used for the treatment of symptomatic drug-refractory...
It was announced recently that Bardy Diagnostics (BardyDx) has entered into a distribution agreement with JNC Medical, a distributor of medical technologies based in Ottawa, Canada. The agreement grants JNC Medical the right to distribute the BardyDx Carnation Ambulatory...
Patients with a previous diagnosis of atrial fibrillation who were assessed as attending the emergency department inappropriately did so because of fear, or as a result of advice from another person or self-monitoring, a study has found. Benedict Glover...
Sabine Ernst and Mattias Duytschaever are both consultant cardiologists and scientific committee members of the practical and scientific faculty of the Atrial Fibrillation Symposium, a long-standing initiative from Biosense Webster and the Johnson & Johnson Institute. Here, they talk...
Recent years have seen many advances in education for cardiologists, but little attention has been paid to the impact of new technologies, particularly digital platforms and social networking. Digital education is evolving so rapidly that most patients, clinicians, and...
Malini Madhavan (Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA) and others reported the results of a study in American Heart Journal that found that patients with atrial fibrillation who have cognitive impairment or are frail were less likely...
Ahmad Masri (Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA) and others report in JACC: Clinical Electrophysiology that a systematic review and meta-analysis of the available evidence on the use of wearable cardiofibrillator therapy (WCD)...
A study carried out at the New York University Langone Health Electrophysiology Lab (New York, USA) showed significantly reduced radiation exposure levels after implementing a radiation safety time out before all electrophysiology procedures. Anthony Aizer (New York University School...
In a new financing round, Kardium has raised an undisclosed amount to fund commercial activities in Europe and Canada, and for clinical testing of the Globe system in the USA. The financing was led by funds and accounts advised by T Rowe...
A press release reports that the first patient has been enrolled in the ICE-AFIB clinical trial (AtriCure). Following Investigational Device Exemption (IDE) approval by the FDA, the first patient was treated by Niv Ad, at Washington Adventist Hospital in...
Vectorious Medical Technologies has announced the initiation of the VECTOR-HF first-in-human (FIH) clinical trial, and the successful first “in-human” implantation of the V-LAPTM monitoring device. A press release reports that the trial will enrol up to 30 patients six...
A new report from Biosense Webster sets out the scale and impact of atrial fibrillation (AF) across Europe and calls for greater awareness and understanding around the effects of AF, the need for earlier detection and diagnosis of this...
A newer type of blood-thinning medications, non-vitamin K oral anticoagulants (NOACs), is now recommended as the preferred alternative to warfarin for reducing the risk of stroke associated with atrial fibrillation (AFib), according to a focused update to the 2014...
Highlights: "No serious adverse outcomes" with ICD shocks in young athletes playing sport Computerised-decision support has the potential to be a "powerful tool" for preventing cardiovascular events in AF patients Profile: Haran Burri Richard Sutton: The first 60 years...
The editors-in-chief of major cardiovascular journals—of both US and European societies—have come together to “sound the alarm” about the dangers of medical misinformation that has been disseminated through the internet, social media, and other platforms. They claim that this...
The British Heart Foundation (BHF) has announced that it is now accepting proposals for its Big Beat Challenge—a single funding award of £30 million. The goal of the Challenge, according to a press release, is to push teams of researchers...
Medtronic has announced that it has entered into a definitive agreement to acquire EPIX Therapeutics. When completed, the EPIX acquisition will expand the Medtronic cardiac ablation portfolio. The DiamondTemp (TM) ablation system (EPIX) provides physicians with improved feedback and control...
Approval has been granted for Abbot’s TactiCath Contact Force Ablation Catheter, Sensor Enabled, which is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation. A new ablation catheter designed to help physicians...
The US government shutdown means the country’s Food and Drug Administration (FDA) cannot accept new user fees, which means the agency cannot accept new medical product applications. FDA commissioner Scott Gottlieb took to Twitter to highlight agency employees who are...
Obstructive sleep apnoea and atrial fibrillation (AF) have presented many challenges, including identifying which patients need to be assessed for obstructive sleep apnoea and the current management options. Caroline Broughton, Shahbaz Piracha and Martin Allen write in Cardiac Rhythm...
Simultaneous monitoring of autonomic tone and ectopic activity could be used to prevent the occurrence of postoperative atrial fibrillation (POAF). Flavia Ravelli (Department of Physics, University of Trento, Povo-Trento, Italy) and the colleagues of the Cardiovascular Department of the...
Cambridge Heartwear is announcing the launch of their company and release of their Heartsense monitor in 2019. In the US, strokes are among the leading causes of death and heart disease is the leading killer. National and international data...
It has been announced that Bardy Diagnostics has monitored over 40,000 patients driven by rapid adoption of the Carnation Ambulatory Monitor (CAM), the world's first P-wave centric ambulatory cardiac patch monitor and arrhythmia detection device. The significance of the CAM patch's P-wave focused clinical...
iRhythm Technologies has announced the publication of a new study in Nature Medicine showing expert-level detection of cardiac arrhythmias using a new deep learning, or artificial intelligence, approach for electrocardiogram (ECG) analysis across a variety of diagnostic classes. The findings...
Premarket Approval (PMA) from the US Food and Drug Administration (FDA) has been granted for the VASCADE MVP Venous Vascular Closure System (Cardiva Medical). VASCADE MVP is the first and only vascular closure system designed and labelled specifically for...
Writing in Circulation: Cardiovascular Quality and Outcomes, David Ouyang (Stanford University, Falk Research Center, Palo Alto, USA) and others report that while the number of female first and senior authors of cardiovascular research papers has increased over the past...
BioCardia has announced its 510(k) submission for US FDA clearance of the Avance steerable introducer, which is designed for introducing various cardiovascular catheters into the heart, including via the left side of the heart through the interatrial septum. A...
Sixty years ago, the first pacemaker implant was made in Stockholm, Sweden (Senning & Elmqvist) on 8 October 1958. The patient had atrioventricular block with recurrent Adams-Stokes attacks. These were prevented by the implant—although, it only functioned for a...
The first patient has been treated in the TERMINATE AF trial (Medtronic). This is a multi-centre study evaluating two surgical ablation devices—the Cardioblate irrigated RF (IRF) system and the CryoFlex surgical ablation system—for the treatment of non-paroxysmal (persistent or...
Biosense Webster has enrolled and treated the first patient in its STELLAR US investigational device exemption (IDE) study. The study will evaluate the safety and effectiveness of Heliostar multi-electrode radiofrequency balloon ablation vatheter in treating symptomatic drug refractory recurrent...
CardioFocus has completed enrolment in a trial to evaluate its next-generation HeartLight X3 endoscopic ablation system. According to a press release, a total of 60 patients have been treated in this pivotal confirmatory trial with a one-month follow up....
A post-hoc analysis of the ICD Sports Registry—which has already indicated that many patients with implantable cardioverter defibrillators (ICD) can safely participate in vigorous or competitive sports—shows that shocks are not infrequent in young ICD patients who play competitive...
Data presented at the 2018 American Heart Association (AHA) scientific session scientific sessions (10–12 November, Chicago, USA) indicate that the use of alert-based computerised-decision support significantly increases the rate of anticoagulation prescription among patients who are hospitalised with atrial...
Quentin Fischer (Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada) and others report in Circulation: Cardiovascular Interventions that patients with pre-existing left bundle branch block (LBBB) have a significantly increased risk of requiring permanent...
Abbott has announced the start of LESS-VT—the first US clinical trial to evaluate the safety and effectiveness of ablation treatment for patients with monomorphic ventricular tachycardia. The LESS-VT study, which is currently enrolling patients, will evaluate the safety and...

Tim Betts

For Tim Betts, a career in medicine was a natural choice. After graduating he knew he wanted to be a cardiologist and, with a fascination for arrhythmias and ECGs, he became hooked on electrophysiology. His research is focused on...
Data from an open-label, pilot randomised trial (TRED-HF) indicate that if heart failure treatment is withdrawn in patients with recovered dilated cardiomyopathy, many will relapse and require treatment to be reinitiated. These findings suggest that until predictors of relapse...
The US FDA has announced plans to modernise its 510(k) clearance programme for approving medical devices for the US market. Data show that about 20% of current 510(k) devices are approved on trials that compare novel devices to predicate...
During AF Association Global AF Aware Week, Biosense Webster EMEA has published a report that uncovers the growing burden of atrial fibrillation (AF) on patients, caregivers and healthcare systems across Europe. The new report is calling for greater awareness and...
New harmonised outcome measures for atrial fibrillation (AF) have been published in HeartRhythm. The work was funded by the Agency for Healthcare Research and Quality (AHRQ) through an interagency agreement with the Office of the Secretary Patient Centered Outcomes...
Positive 12-month data have been presented for the roll-in cohort of the pivotal CardiAMP Heart Failure Trial studying the investigational CardiAMP Cell Therapy System (BioCardia) in adult patients experiencing heart failure following a heart attack. The results were presented...
The VASCADE MVP (Cardiva Medical), a vascular closure system designed specifically for multi-access venous closure following electrophysiology procedures such as arrhythmia ablation, met its endpoints compared to manual compression in a pivotal clinical study. The AMBULATE study is the...
People who experience migraine with visual aura may have an increased risk of atrial fibrillation, according to a study published in the online issue of Neurology, the medical journal of the American Academy of Neurology. Migraine with visual aura is...
An international study, led by researchers from the Intermountain Medical Center Heart Institute in Salt Lake City, found that a smartphone app (AliveCor) to monitor heart activity and determine if someone is having an ST-segment elevation myocardial infarction (STEMI) has...
Maisense, a start-up company specialising in stroke prevention, has recently introduced an AI-based solution that can screen stroke through early detection of atrial fibrillation (AF), that will also be presented at MEDICA (12–15 November, Düssledorf, Germany). Patients with AF have...
EPIX Therapeutics, a medical device company that designs and manufactures a catheter-based system for the treatment of patients with atrial fibrillation (AF), has announced achievement of the enrolment goal of the DIAMOND-AF study, a global FDA-approved IDE pivotal study...
Cardiva Medical, an innovator in the field of vascular closure, has announced that new data from the randomised AMBULATE study will be presented in a late-breaking session on new trials in cardiovascular care at Scientific Sessions 2018, the annual...
The American College of Cardiology, the American Heart Association and the Heart Rhythm Society have released a guideline for the evaluation and treatment of patients with bradycardia, or a slow heartbeat, and cardiac conduction disorders. In the guideline, bradycardia is...
Highlights: Novel anticoagulants associated with lower all-cause mortality compared to VKAs CABANA trial provides important new data on clinical and quality of life effects of ablation for atrial fibrillation Profile: Tim Betts New guidelines on CV management during pregnancy
Highlights: Novel anticoagulants associated with lower all-cause mortality compared to VKAs CABANA trial provides important new data on clinical and quality of life effects of ablation for atrial fibrillation Profile: Tim Betts New guidelines on CV management during pregnancy
Researchers at Stanford University's School of Medicine have completed enrolment of a large-scale study using the Apple Watch to determine whether a wearable technology can identify atrial fibrillation. The study rationale and design, published in the American Heart Journal,...
Cardiac Insight, Inc., a developer of wearable cardiac biosensors and clinical diagnostic software systems featuring proprietary automated data analysis algorithms, has announced its partnership with VivoSense, a company focused on integration and specialised analysis of wearable sensor data for...
The HeartMate 3 left ventricular assist device has received US FDA approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for...
A new meta-analysis of patients undergoing percutaneous closure of patent foramen ovale (PFO) after cryptogenic shock supports previous studies that indicate PFO closure is associated with an increased risk of atrial fibrillation. However, it also shows that device-related atrial...
Cardialen, a medical device company developing a low-energy implantable defibrillation therapy designed to more gently restore normal heart rhythm, has announced the closing of a US$17 million Series B investment led by RiverVest Venture Partners, along with Qiming Venture Partners,...
Medtronic has issued a software update "to address a safety risk caused by cybersecurity vulnerabilities" in 34,000 of their cardiac implantable electronic devices (CIEDs), the US FDA write in a safety communication to healthcare professionals. Following a review of...
CathVision, an early stage medical device company developing an advanced cardiac electrophysiology recording system, CUBE, has announced that the company received ISO 13485:2016 certification for Medical Device and Quality Management Systems from Lloyd's Register. This ISO certification indicates that the...
Adagio Medical, the developer of the iCLAS technology—the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias—announces that the first patients were successfully treated with its new One Shot+ cryoablation catheter. The new catheter...
Johnson & Johnson have announced that Biosense Webster has received approval from the US Food and Drug Administration (FDA) for its VISITAG SURPOINT External Processing Unit and enrolment has begun in its post-market approval study. The VISITAG SURPOINT Module calculates...
New guidelines for the management of cardiovascular diseases during pregnancy, including upgraded recommendations of catheter ablation and risk-dependent action plans, were presented by Carina Blomström-Lundqvist, Uppsala University, Uppsala, Sweden, at the European Society of Cardiology Congress (ESC; 25–29 August,...
LivaNova has announced the first successful implantation of the Vitaria system in a patient enrolled in the Autonomic regulation therapy to enhance myocardial function and reduce progression of heart failure with reduced ejection fraction (ANTHEM-HFrEF) pivotal study. The study...
AtaCor Medical has announced that it has completed a US$8.8M Series A financing. Co-led by Boston-based Broadview Ventures and Israel-based aMoon Ventures, the financing also includes participation from a corporate partner. The investment will support the continued development of...
This article has been sponsored by Abbott Case description A 31 year-old female with tricuspid atresia and normally related great vessels who underwent an atriopulmonary Fontan (total cavopulmonary anastomosis) at two years of age and a subsequent Fontan revision to a...
Amit N Vora (Duke University Medical Center/the Duke Clinical Research Institute, Durham, USA) and others report in in JACC: Cardiovascular Interventions that patients who develop atrial fibrillation after undergoing transcatheter aortic valve implantation (TAVI) have a higher risk of...
Transvenous lead extraction in cardiac resynchronisation therapy (CRT) patients is not associated with increased 30-day mortality vs. non-CRT patients. The study found that age, renal impairment and sepsis were independent predictors of 30-day mortality and sepsis was the main...
Four out of ten patients with atrial fibrillation but no history of stroke or transient ischaemic attack have previously unknown brain damage, according to the first results of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF) presented at European Society...
Atricure have announced that the enrolment of the full cohort of 153 patients in the CONVERGE IDE clinical trial has been completed. CONVERGE IDE is the first prospective, randomised study comparing the Convergent approach to endocardial catheter ablation in persistent...
New findings from the CRYO4PERSISTENT AF clinical trial demonstrate improved quality of life, reduced symptoms from abnormal heart rhythms, and low incidence of reinterventions and repeat ablation procedures. The study evaluated patients with symptomatic persistent atrial fibrillation (AF) treated...
Biotronik is now the exclusive US distributor for InfoBionic's MoMe Kardia external cardiac diagnostic monitor, it has announced in a press release. The device benefits patients suspected of experiencing cardiac arrhythmias and is designed to increase early detection and...
Thomas S Gilhofer (University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland) and others report in Structural Heart that a combined procedure involving both transcatheter aortic valve implantation (TAVI) and left atrial appendage closure is a feasible...
At the 2018 European Society of Cardiology (ESC) Congress (25–29 August, Munich, Germany), British Heart Foundation (BHF) announced the “Big Beat Challenge”—an £30m award that seeks to bring together world-leading researchers and innovators to identify and solve any of...
At the 2018 European Society of Cardiology (ESC) Congress (25–29 August, Munich, Germany), Siemens Healthineers launched Magnetom Sola Cardiovascular Edition—a 1.5 Tesla magnetic resonance imaging (MRI) scanner that is specifically designed for cardiovascular examinations. A press release reports that...
WeHealth, by Servier, has launched Cardioskin—a connected solution that is designed to function as an ambulatory wearable 15-lead ECG—at the 2018 European Society of Cardiology Congress (25–29 August, Munich, Germany). A press release reports that Cardioskin is composed of...
Royal Philips has introduced the EPIQ CVx cardiovascular ultrasound system. Built on the powerful EPIQ ultrasound platform, EPIQ CVx is specifically designed to increase diagnostic confidence and simplify workflow for clinicians, giving them more time to interact with their...
More than 100,000 people have been trained in hands-only cardiopulmonary resuscitation (CPR) since the American Heart Association (AHA) launched its hands-only CPR training kiosk programme in 2016. As part of the programme, that is supported by Anthem Foundation in...
A feasibility study of a novel left atrial appendage device (Ultraseal, Cardia) indicates that the device is associated with a high rate of procedural success and a fast learning curve. It also suggests that the device has an extremely...
BioSig Technologies have announced that the Company has received 510(k) clearance for its first product, PURE EP System, from the US Food and Drug Administration (FDA). The non-invasive PURE EP System is a computerised system intended for acquiring, digitising, amplifying,...
Milestone Pharmaceuticals, a clinical-stage cardiovascular company, announced that the first patient has been randomised in its phase 3 clinical study of etripamil. Etripamil is a new investigational, rapid-onset, short-acting calcium channel blocker administered intranasally by the patient designed to...
Medtronic plc have announced the start of a pilot study of its investigational extravascular implantable cardioverter defibrillator (EV ICD) system, in which a lead is placed outside of the heart and veins to deliver lifesaving defibrillation and antitachycardia pacing...
A new study, published in JAMA Network Open, indicates that patients with atrial flutter have a lower incidence of stroke than patients with atrial fibrillation who have the same CHA2DS2-VASc score. Given current European guidelines advise that patients with...
VisCardia has announced the first implant of its VisONE implantable system for heart failure, and the commencement of its VisONE Heart Failure pilot study in Ukraine. According to a press release, the VisONE implantable system delivers VisCardia’s proprietary asymptomatic...
How to best combine optimal screening and diagnosis for atrial fibrillation (AF) has long been a challenge. At European Heart Rhythm Association Congress (EHRA; 18–20 March 2018, Barcelona, Spain) Jens Eckstein (University of Basel, Basel, Switzerland) presented the case...
A study looking at patients undergoing lead extraction found that they were more likely to survive superior vena cava tears when treatment included the Bridge occlusion balloon. Lead author, Roger Carrillo (University of Miami, Miami, USA) concluded that when...
Cyber security has become a hot topic in recent years. Leslie Saxon writes in Cardiac Rhythm News about the cybersecurity risks for implantable cardiac devices. In the past year, the US FDA and a division of Homeland Security that responds...
The American Heart Association (Association) and Laerdal Medical (Laerdal) are furthering their decades-long alliance to deliver a new standard of resuscitation quality and patient care centred on CPR competence. Attendees representing 30 of the nation’s largest health care systems...
MEDICALgorithmics and US subsidiary Medi-Lynx Cardiac Monitoring L.L.C., have announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the PocketECG Cardiac Rehabilitation System (CRS), a new mobile cardiac rehabilitation system designed to provide high-quality...
A phase 3 trial of Zoll Medical’s LifeVest has missed its primary endpoint. The study found that people who started using the wearable defibrillator the week after they had a heart attack did not experience a statistically significant reduction...
Boston Scientific has signed an agreement to acquire Claret Medical, which developed and commercialised the Sentinel cerebral embolic protection system. The device is used to protect the brain during certain interventional procedures, predominately in patients undergoing transcatheter aortic valve...
Medtronic has announced the first enrolments in a new clinical trial evaluating the ECG (electrocardiography) Belt Research System (ECG Belt) as a diagnostic tool for optimising cardiac resynchronisation therapy (CRT) for patients with heart failure. The first patient enrolled...
The link between cardiac diseases and stroke is well known and reported. Wolfram Döhner writes in Cardiac Rhythm News about the needs for interdisciplinary thinking and collaboration. Stroke is a leading cause of death and the main cause of physical...
His bundle pacing was successful in 92% of patients and the primary endpoint of death, heart failure hospitalisation or upgrade to biventricular pacing was significantly reduced in the His bundle pacing group. Right ventricular pacing is associated with heart...
Symptomatic atrial fibrillation (AF) patients with previous failed catheter ablation or structural changes associated with higher recurrence of AF could benefit from thoracoscopic ablation and left atrial appendage excision. The thoracoscopic approach was associated with higher initial rates of...
Bardy Diagnostics has announced that it has raised additional growth capital from its existing equity investors, including SV Health Investors ("SVHI"), Health Enterprise Partners, and Ascension Ventures. The growth capital will be used to expand BardyDx's sales force and...
The mHealth Screening To Prevent Strokes (mSToPS) randomised clinical trial showed that home-based wearable electrocardiogram (ECG) sensor patch monitoring, compared with delayed monitoring, resulted in a higher rate of atrial fibrillation (AF) diagnosis after four months. Wearing an ECG patch...
Differences between men and women mean that outcomes after cardiac events can differ between the sexes. Cecilia Linde writes in Cardiac Rhythm News about a new consensus document that looks to address these issues. There is an increasing awareness that...
A press release has announced US Food and Drug Administration (FDA) labeling expansion for the Medtronic SelectSecure MRI SureScan Model 3830 cardiac pacing lead to include stimulation of the bundle of His. It is the only pacing lead on...
A press release reports that the CALYPSO programme will receive 14 million euros to develop CorWave Neptune—a new type of cardiac support designed to improve the management of patients with severe heart failure—as part of the Programme d’Investissements d’Avenir(PIA)...
Medtronic has received United States Food and Drug Administration (FDA) approval for a less-invasive implant approach of its HVAD System, a left ventricular assist device (LVAD) for patients with advanced heart failure. The HVAD System is the smallest commercially...
Black people who survive cardiac arrest during hospitalisation have lower odds of long-term survival compared with similar white survivors, according to new research published in Circulation.  Half the difference in one-year survival rates, however, remained unexplained. Nearly one-third of the racial...
CorWave has announced that it has obtained patent no. US 9,968,720 B2 on May 15, 2018 from the US Patent and Trademark Office. Titled “Implantable pump system having an undulating membrane,” according to a press release, this patent describes...
Research finds use of smaller, self-contained devices reduced complications for up to 18 months compared with conventional designs The findings of the research, led by Ohio-based Cleveland Clinic, appeared in the journal Heart Rhythm. The study compared patient outcomes for...
CorWave obtained patent no. US 9,968,720 B2 on May 15, 2018 from the United States Patent and Trademark Office. Titled “Implantable pump system having an undulating membrane,” the patent describes the application of CorWave’s technology for blood pumping in a...
This article was sponsored by Abbott. Left ventricular assist devices (LVAD) are mechanical pumps that are implanted inside a person's chest to help their weakened heart ventricle pump blood throughout the body. The mechanical device supports the left heart chamber...
As part of its plan to expand it atrial fibrillation ablation therapy offering, Boston Scientific Corporation has announced a definitive agreement to acquire Cryterion Medical, a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation...
Investigators at Children's Hospital Los Angeles and the University of Southern California, Los Angeles, USA, have demonstrated the feasibility of implanting a micropacemaker system in the pericardial sac surrounding the heart — a breakthrough that may open up new cardiac pacing...
By Hannah Woolley Findings from the Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS) trial suggest that the combination of low-dose rivaroxaban and aspirin significantly lowers the incidence of both major adverse cardiovascular...
The annual census of UK consultants and higher speciality trainees—Focus on Physicians 2017–18—indicates that more than half of all consultants and two thirds of trainees reported frequent gaps in trainees’ rotas, with one in five respondents saying these are...
By Hannah Woolley In a multivariate analysis including both BRUISE CONTROL 1 and BRUISE CONTROL 2 patients and adjusted for antiplatelet use, there was no difference in clinically significant haematoma between direct oral anticoagulants (DOACs) and warfarin. Oral anticoagulant use is...
By Hannah Woolley Longer dwell times are related to higher rates of complication during lead extraction. There have been various studies looking at the risk factors for transvenous lead extraction but there is limited knowledge about extraction of leads that...
Patients with scar-related ventricular tachycardia (VT) do not often achieve a cure. Jason S Bradfield and Kalyanam Shivkumar write in Cardiac Rhythm News about how to tackle this issue. Success with medical therapy or catheter ablation may involve long periods...
HeartSciences has announced that it has been highlighted as a “Start-Up to Watch” in the June 8, 2018 issue of the MedTech Strategist. The article titled “Heartsciences: artificial intelligence improves frontline risk stratification for heart diseases” discusses HeartSciences’ role...
Wearable cardioverter defibrillators – vest-like devices that deliver electric shocks to interrupt a dangerous heart rhythm – may be a safe and effective alternative to surgically implanted devices in children with ventricular heart rhythm disorders that put them at risk for...
Catheter ablation for atrial fibrillation (AF) produced no significant improvement in death, disabling stroke, serious bleeding, or cardiac arrest but did reduce death or cardiovascular hospitalization and recurrent AF in the Catheter Ablation versus Antiarrhythmic Drug Therapy (CABANA) trial,...
Published in the heart journal Europace, the researchers found that a 10% loss in weight along with management of associated risk factors, can reverse the progression of the disease. They studied 355 overweight or obese people who lost varying amounts...
New guidance regarding the selection and evaluation of wearable devices for use in regulatory trials and to support labelling claims has been published in the journal Value of Health. The report, Selection of and Evidentiary Considerations for Wearable Devices and...
The US Food and Drug Administration (FDA) released the following two draft guidance documents: These guidance documents provide industry and FDA staff with recommendations on the least burdensome means of assessing the performance of catheters, guidewires, and delivery systems submitted...
The first-in-human phase I trial will take place in Australia for Verseon’s PROAC (PRecision Oral AntiCoagulant) VE-1902, which has successfully completed regulatory toxicology studies and was well-tolerated in 28-day repeat dosing. PROACs are a novel class of anticoagulants that show...
A new study has found that the more alcohol you drink, the higher your heart rate gets. These finding were presented at European Heart Rhythm Association Congress (EHRA; 18–20 March 2018, Barcelona, Spain). The Munich Beer Related Electrocardiogram Workup (MunichBREW)...
The trials found that ultralow temperature cryoablation is feasible and shows excellent safety and efficacy. The clinical outcomes for flutter ablation show a 94% success rate at three months. Ultralow temperature ablation uses near-critical nitrogen. The catheter operates at the...
The algorithm (Kardiaband, AliveCor) for atrial fibrillation (AF) detection, when supported by physician review can accurately differentiate AF from sinus rhythm (SR). This technology can help screen patients prior to elective cardioversion and avoid unnecessary procedures. One hundred patients were...
The American Heart Association has announced research grants totalling more than US$28 million to the scientific teams that will create a new research network focused on understanding the causes of atrial fibrillation (AFib). The new knowledge they discover will...
BIOTRONIK have announced the opening of its Education and Innovation Centre in Ebisu, Tokyo, Japan. The centre will provide the latest educational programs and services for medical professionals and respond to the needs of medical practitioners through efficient information...
The American College of Cardiology (ACC), Heart Rhythm Society (HRS), North American Society for Cardiovascular Imaging (NASCI), Society for Cardiovascular Angiography and Interventions (SCAI), and the Society for Computed Tomography (SCCT) have published, in the Journal of the American...
Zenicor Medical Systems AB has been selected as sole supplier for a screening programme in the UK for atrial fibrillation. The screening programme is the world’s largest randomised controlled trial to discover whether screening systematically for atrial fibrillation, a...
Royal Philips has announced that it has signed an agreement to acquire EPD Solutions. EPD’s cardiac imaging and navigation system helps electrophysiologists navigate the heart by generating a detailed 3D image of the cardiac anatomy, while also pinpointing the...
The United States Food and Drug Administration (FDA) has classified Medtronic recent voluntary urgent field action related to the HeartWare HVAD System unexpected power source switching as a Class I recall. Class I recalls describe situations where there is...
The total procedure-related complications after surgical minimally invasive pulmonary vein isolations (MIPI) were higher; this was mainly due to more major complications. During a two-year follow-up there were three transient ischaemic attacks or cerebrovascular accidents after MIPI compared to...
Researchers will use a European network of 90,000 patients, including 20,000 DNA samples, to look at different approaches for prevention and treatment of sudden cardiac arrest for men and women. Sudden cardiac arrest is the consequence of the heart rhythm...
Apixaban and warfarin are equally safe during catheter ablation of atrial fibrillation, according to results of the AXAFA-AFNET 5 (Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy) (German...
The Copenhagen City Heart Study set out to investigate whether left atrial (LA) functional measures predict atrial fibrillation (AF) in the general population. They found that LA functional measures predict AF in the general population and can provide prognostic...
The first systematic evaluation of coagulation point-of-care testing in edoxaban treated patients has been carried out. The results were presented by Florian Härtig, University of Tuebingen, Germany, at the International Stroke Conference (ISC; 24–26 January 2018, Los Angeles, USA) Currently...
The interim results of the REAFFIRM (Randomised Evaluation of Atrial Fibrillation treatment with Focal Impulse and Rotor Modulation guided procedures) trial showed there was no statistically significant difference in outcomes between the treatment and control arms. These results were...
Octreotide therapy has the potential to offer atrial fibrillation (AF) patients with arteriovenous malformations (AVM) related gastrointestinal (GI) bleeding another treatment option. It is a safe way to reinitiate oral anticoagulants (OACs) by bringing down the risk of repeat...
One-year results from the Dielectric Unravveling of RAdiofrequency ABLation Effectiveness (DURABLE-I) clinical trial have shown that the KODEX (Navix International Limited) system help to improve effectiveness by detecting gaps in real time during the index ablation procedure. The results...
The results of the WATCH AF trial, the world’s first international, prospective and double-blinded clinical trial (ClinicalTrials.gov ID: NCT02956343) evaluating the accuracy of a smartwatch to detect atrial fibrillation were announced at the European Heart Rhythm Association Congress. (EHRA...

Dhanunjaya Lakkireddy

Dhanunjaya Lakkireddy is executive medical director at The Kansas City Heart Rhythm Institute at HCA Midwest Health, Kansas, USA. He holds the title Professor of Medicine, is board certified in Cardiology and Electrophysiology and is a renowned electrophysiologist. He...

Luigi Di Biase

Luigi Di Biase is a prominent electrophysiologist, section head of Electrophysiology, director of Arrhythmia Services, and professor of Medicine (Cardiology) at the Albert Einstein College of Medicine, New York, USA. In addition, he serves as senior researcher at the...
Highlights: Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation and may have a positive effect on cognitive function Stroke prevention drugs may help reduce dementia risk for atrial fibrillation patients, consensus document finds Leslie...
Highlights: Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation and may have a positive effect on cognitive function Stroke prevention drugs may help reduce dementia risk for atrial fibrillation patients, consensus document finds Leslie...
Boston Scientific Europe has announced the launch of the HeartLogic Heart Failure Diagnostic in Europe. With this launch, the first and only diagnostic tool that enables proactive heart failure (HF) care is now available for patients in select countries...
iRhythm Technologies has announced results of a study which utilised Zio by iRhythm, an extended continuous cardiac monitoring system, to provide a comprehensive picture of the burden of atrial fibrillation (AF) in patients. Utilising this data in combination with...
Results from a research study demonstrating the feasibility of a novel approach to delivering pacing and defibrillation therapy in which a lead is placed under the sternum (breastbone), outside of the heart and veins have been announced. Data from...
Study results show that the AdaptivCRT algorithm is associated with improved patient survival. The real-world, prospective registry of 1,835 patients, use of the AdaptivCRT algorithm was associated with a 31% relative reduction in all-cause mortality compared to conventional cardiac...
Results from an analysis of the LATITUDE database which evaluated the successful reduction of inappropriate shocks using the SMART Pass sensing filter in patients implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) System have been announced. The real-world data...
The AngelMed Guardian System is an implantable cardiac monitor intended to detect and alert patients of a potential heart attack. The Guardian System consists of three components: The Implantable Medical Device (IMD), which monitors the heart's electrical activity (electrograms)...
Two-year results show rivaroxaban was associated with reduced stroke and systemic embolism versus warfarin, without altering risk of major bleeding. The study evaluated efficacy and safety of rivaroxaban, apixaban and dabigatran each versus warfarin. The Janssen Pharmaceutical Companies of Johnson...
The US FDA has issued a class I recall due to a malfunction in the device’s outflow graft assembly that may cause the outflow graft to twist and close up (occlusion) over time. Occlusion of the outflow graft can...
Jagmeet Singh is the founding director of the Resynchronisation and Advanced Cardiac Therapeutics Program. Singh is the principal investigator for the Personalised CRT-MPP Post-Approval Study and a paid consultant for Medtronic. In this commentary he discusses his research on...
The American Heart Journal has published the results of a head-to-head comparison of two patch-based arrhythmia monitoring systems. The study, "Comparison of two ambulatory patch ECG monitors: The benefit of the P-wave and signal clarity" concluded that the BardyDx...
Investigators from the Mayo Clinic and AliveCor demonstrated that a trained artificial intelligence network can help identify people with increased risks of arrhythmias and sudden cardiac death, despite displaying a normal heart rhythm on their electrocardiogram. Up to half...
The SMART Pass sensing filter (Boston Scientific), when in patients implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) System, successfully reduces inappropriate shocks. This is the result of an analysis of the LATITUDE database, presented during a late-breaking clinical...
Cardiac contractility modulation (CCM) in heart failure is safe, the results from the FIX-HF-5C randomised controlled trial demonstrate, with all primary and secondary safety endpoints met. The results were presented by William Abraham (Internal Medicine, Division of Cardiovascular Medicine,...
An investigational algorithm, utilising the accelerometer signal in the Micra Transcatheter Pacing System (TPS) (Medtronic) may restore AV synchrony, improving cardiac function in patients with sinus rhythm and atrioventricular (AV) block, the results of a new clinical study show. The...
The first patient has been enrolled and treated in the QDOT AF study (Biosense Webster). The study will evaluate the delivery of high power, short duration ablation with QDOT MICRO, a novel radiofrequency (RF) ablation catheter for the...
Abbott has announced US Food and Drug Administration (FDA) clearance of the Advisor HD Grid mapping catheter, sensor enabled. Advisor HD Grid employs a new design that allows physicians to see things differently, capturing and analysing data in a novel...
This article has been sponsored by Boston Scientific. Case description A 62-year-old woman, with recent sinus venosus atrial septal defect correction surgery, developed a persistent macroreentrant atrial tachycardia and macroreentrant atrial tachycardia (MAT) ablation was performed. The diagnosis of this congenital...
 Acutus Medical has announced that the AcQMap High Resolution Imaging and Mapping System has been utilised for the first time in US patients. The company also revealed initiation of a new clinical study to evaluate the technology during atrial...
Preventice Solutions has announced the launch of the BodyGuardian Mini, the smallest, reusable long-term Holter technology available for cardiac monitoring. The new, compactly designed technology includes an ultra-small, lightweight cardiac monitor that enables up to 14-days of ECG measurements...
The US Food and Drug Administration (FDA) has granted approval for the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of paroxysmal atrial fibrillation (PAF). The Excalibur Balloon leverages the proven universal balloon design of the company's FDA-approved HeartLight Endoscopic Ablation System and...
The CARTO VIZIGO Bi-directional Guiding Sheath is now available in the United States. This is the first commercially available steerable guiding sheath that can be visualised on the CARTO 3 System during a catheter ablation procedure, helping electrophysiologists reduce dependency...
Stereotaxis has announced a strategic collaboration to integrate the Stereotaxis Niobe Magnetic Navigation System and the Acutus Medical AcQMap High Resolution Imaging and Mapping System with the goal of improving patient care and the physician experience in electrophysiology. “I was...
At the AF Symposium (11–13 January 2018, Orlando, USA) John Camm, St George’s University of London and Imperial College, London, UK, looked at the current status of screening for atrial fibrillation (AF). This is as an area of controversy...
The HAVOC score was developed following the CRYSTAL-AF study, to see if there was an easier way to identify which patients with atrial fibrillation were most at risk of stroke. Susan Zhao, Santa Clara Valley Medical Center, San Jose,...
More patients than ever before are being given NOACs due to their relative stability and safety, but the risk of gastrointestinal bleeding with NOACs is higher than with warfarin. This has led researchers to look for new ways of...
Results from a multicentre study of catheter ablation guided by DEEP (decrement-evoke potential) mapping show that using DEEP mapping meant that ablation was successful in the majority of patients and they could no longer be induced into clinical ventricular...
Medical devices, including cardiovascular implantable electronic devices could be at risk for hacking. In a paper published in the Journal of the American College of Cardiology, the American College of Cardiology’s Electrophysiology Council examines the potential risk to patients...
Local activation mapping at sites of termination of persistent atrial fibrillations (AF) shows repetitive patterns including rotational or focal activity reports a study in Circulation: Arrhythmia and Electrophysiology. Therapy for persistent atrial fibrillation is limited by uncertainty about sustaining mechanisms....
2017 was a year of big results for catheter ablation, continuing the procedure’s steady rise in atrial fibrillation (AF) management. Mark O’Neill, consultant cardiologist and professor of Cardiac Electrophysiology at St Thomas’ Hospital and King’s College London, UK, spoke...

Nassir Marrouche

Nassir Marrouche is a prominent electrophysiologist, executive director of the Comprehensive Arrhythmia Research and Management (CARMA) Centre at the University of Utah in Salt Lake City, USA, and director of the Western Atrial Fibrillation Symposium (23–24 February 2018, Park...
Highlights: Real-time lesion formation and gap detection during ablation: DURABLE-I follow-up Octreotide enables left atrial appendage closure in AF patients with GI bleeding M Edip Gurol: Brain MRI scans can inform the choice between OACs and LAA closure for non-valvular...
LivaNova has finalised the US$190 million sale of its cardiac rhythm unit to MicroPort Scientific. The final terms of the deal commit LivaNova to paying up to US$20 million in indemnity linked to a probe initiated by antitrust officials around...
The US FDA has approved a firmware update that is now available and is intended as a corrective action (recall), to reduce the risk of patient harm due to premature battery depletion and potential exploitation of cybersecurity vulnerabilities for...
A medical device company has announced the results of a clinical study serially conducted at The Icahn School of Medicine, Mount Sinai Hospital, New York, USA and the West Virginia University (WVU) Heart and Vascular Institute, Morgantown, USA. The...
Murj, a healthcare technology company focused on transforming implantable cardiac device management, has announced the availability of OnSite— the industry’s first cloud-based workflow solution for in-office cardiac device management. OnSite is an extension of Murj’s proven workflow for remote transmission...
There is a disparity between indications for and utilisation of implantable cardioverter defibrillators (ICDs) in Asian patients with heart failure, a recent study finds. The results come from a study authored by Yvonne May Fen Chia et al, recently...
A recent study by Marc P Waase (Columbia University Medical Center, New York, USA) et al published in the Journal of the American Medical Association (JAMA) found that abnormal electrocardiograms (ECGs) are common among professional basketball players in the...
Patient safety is the focus of newly published updates to consensus statements that address the use of antithrombotic drugs by individuals who may require regional anaesthesia or interventions targeting acute or chronic pain. The lengthy statements, published in tandem in...
This video has been sponsored by LivaNova. Sleep apnoea is a major chronic disease that can have cardiovascular consequences. Around 40–50% of people with atrial fibrillation (AF) have obstructive sleep apnoea, rising to around 60% in patients with implantable cardiac...
Boston Scientific have announced the acquisition of Securus Medical Group, a privately-held company that has developed a thermal monitoring system for the continuous measurement of oesophageal temperature. Boston Scientific has been an investor in Securus since 2016, and the...
Cardiac health apps and wearable clinical technology is on the rise, along with remote monitoring and wireless connection functionality in implantable cardiac devices. While the amount of clinical trials and published papers on new technology in this field is...
    Wendy Tzou (University of Colorado School of Medicine, Denver, USA) and colleagues at the International Ventricular Tachycardia Ablation Center Collaborative group (IVTCC) published two papers (in Heart Rhythm and Circulation: Arrhythmia and Electrophysiology) in 2017 on the potential impact...
M Edip Gurol is a stroke neurologist with particular expertise in the care of patients at high risk for ischaemic (blockage type) strokes and haemorrhages. His research focuses on clarifying the mechanisms of brain small vessel diseases that increase...
Two real-world analyses featuring the AdaptivCRT algorithm reinforce that its use is linked to a reduction in atrial fibrillation (AF) episodes, as well as tied to higher patient activity levels. The results, involving 408 patients with heart failure and...
One-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance Cryoballoon to isolate the pulmonary veins in patients with symptomatic persistent atrial fibrillation (AF). The Arctic Front Advance Cyroablation System is not approved for treating...
The heart is capable of terminating arrhythmias itself after local gene therapy, potentially avoiding the need for patients to undergo painful electric shocks, according to a proof-of-concept study presented at EHRA 2018, a European Society of Cardiology congress. Atrial fibrillation...
Patients with atrial fibrillation could reduce the risk of dementia by taking stroke prevention medications, according to recommendations published online in EP Europace1, a European Society of Cardiology journal, and presented at EHRA 2018.2 The international consensus document was...
Data from the TRUE-HD study has been announced during a late-breaking clinical trial session at the annual congress of the European Heart Rhythm Association (EHRA) in Barcelona, Spain. The data demonstrated the RHYTHMIA Mapping System, when paired with the...
Obese patients are at a higher risk of failed first subcutaneous implantable cardioverter-defibrillator (S-ICD) shocks during defibrillation testing. This is what a group from the University of Pennsylvania, CorVita Science Foundation and Boston Scientific Corporation, all USA, found. The...
Low level of daily physical activity was associated with a higher risk of atrial arrhythmias in heart failure patients with implantable devices. A low level of baseline physical activity was also associated with a higher risk of death of...
The first patient has been enrolled and treated in the SHINE clinical study in Europe. The multicentre study aims to evaluate balloon ablation catheter for safety and effectiveness in achieving pulmonary vein isolation in treatment of paroxysmal atrial fibrillation. The...
Interim data from 228 patients (of which 132 were adjudicated for efficacy) showed that AndexXa rapidly and significantly reversed anti-Factor Xa activity (the anticoagulant mechanism of these drugs) when administered as a bolus, and sustained this reversal when followed...
New late-breaking clinical trial data from the MOMENTUM 3 clinical study shows overall survival of 83% at 2-years and marked improvement in clinical outcomes for our patients suffering with advanced heart failure. The data were published online in The New...
EBR Systems has announced enrollment of the first patients in the global SOLVE-CRT (Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronisation Therapy) clinical trial. The first patients were enrolled by Christian Butter at Immanuel Klinikum Herzzentrum Brandenburg in...
iRhythm Technologies has announced primary results of the mHealth Screening to Prevent Strokes (mSToPS) study that evaluated detection of silent atrial fibrillation (AF) in high-risk individuals using Zio by iRhythm. Electrocardiogram (ECG) recording and analysis were carried out using the...
Fysicon has announced that it has been acquired by Canon Medical Systems Corporation (Otawara, Japan).   Linda Elberse, chief executive officer of Fysicon said, "Being part of a major player as Canon Medical Systems Corporation gives us the opportunity to...
AblaCor medical corporation has announced that it has received a notice of allowance from the United States Patent & Trademark Office on five additional patents for its CircumBlator AFib catheter ablation system to advance pulmonary vein isolation ablation procedures for patients with atrial...
Survival from cardiac arrest doubled when a bystander stepped in to apply an automated external defibrillator (AED) before emergency responders arrived, according to new research published in the journal Circulation. Researcher looked at 49,555 cardiac arrests across the USA and...
CardioFocus have announced the initiation of a clinical evaluation of the new HeartLight X3 system for the treatment of AF. Building upon the advanced features of the current HeartLight endoscopic ablation system—direct tissue visualisation, titratable laser energy, and compliant balloon technology—HeartLight X3 is...
Medtronic is recalling certain implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy defibrillators (CRT-Ds) due to a defect in the manufacturing process.  This defect causes an out of specification gas mixture inside the device and may prevent the device...
EPD’s Cardiac Mapping and Navigation System  has received CE mark approval.  The system helps electrophysiologists navigate the heart by generating an accurate 3D map, while imaging and pinpointing the exact location and orientation of catheters in the heart during...
AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, has announced that it has launched the AtriClip FLEX•V Left Atrial Appendage (LAA) Exclusion System in the United States. The new AtriClip FLEX•V is...
The FDA is advising caution before prescribing the antibiotic clarithromycin (Biaxin) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later. The FDAs recommendation is based on a...
Felix Weise (Cardioangiologisches Centrum Bethanien, Frankfurt, Germany) and others report in EuroIntervention that a strategy of six weeks’ duration of dual antiplatelet therapy (DAPT) followed by lifelong aspirin “appears to be a viable alternative” to existing antithrombotic regimens in...
New data from the EXCEL trial, which found that percutaneous coronary intervention (PCI) was non-inferior to coronary artery bypass grafting (CABG) at three years in patients with left main disease, indicate that CABG patients have a significantly increased risk...
Cardiva Medical, an innovator in the field of vascular closure, has announced that the company has closed on US$11 million in additional financing – bringing total equity and debt financing in the current round to US$41 million. The additional financing...
The Food and Drug Administration (FDA) has today issued the final rule on “human subject protection; acceptance of data from clinical investigations for medical devices”. The rule updates the FDA’s standards for accepting clinical data from clinical investigations conducted...
A miniature leadless pacemaker was safe and effective at three years in the first-in-human LEADLESS study, according to a research letter published in Circulation. However, one patient experienced a complication related to battery malfunction, which led to a battery advisory...
African Americans with atrial fibrillation (AF) have a significantly higher risk of stroke than Caucasians with the condition, according to new research published in HeartRhythm by researchers from the Perelman School of Medicine at the University of Pennsylvania, USA. The new findings...
A collaborative study, has found that older patients with atrial fibrillation (AF) undergoing cardiac surgery accompanied with surgical left atrial appendage closure had a lower risk of readmission for thromboembolism over the following 3 years. The study was carried...
Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, and a leader in the diagnosis and treatment of cardiac arrhythmias, recently presented new data evaluating the one-year outcomes of atrial fibrillation (AF) ablation using the CARTO 3 System CARTO...
Written by Hannah Woolley, Cardiac Rhythm News Editor Heart imaging has been successfully used to predict the benefit or futility of catheter ablation. The investigators described their findings in the Journal of the American College of Cardiology: Cardiovascular Imaging. Around 20–30% of...
Philips is recalling the HeartStart MRx defibrillator due to a defect in the device's gas discharge tube. The gas discharge tube has micro cracks which allows internal gasses to escape and causes the tubes to not function as expected....
A recent study by Gry Haaland (University of Bergen, Bergen, Norway) et al published in the Journal of the American Association of Medicine (JAMA): Internal Medicine points to a possible association between warfarin use among patients older than 50...
Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announced it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in...
Highlights: Less bleeding in ablation with interrupted dabigatran compared to uninterrupted warfarin Successful ablation for ventricular tachycardia associated with markedly reduced mortality in advanced heart failure patients Natalia Trayanova: Imaging-based simulations for predicting sudden death and guiding ablation Nassir Marrouche: Profile https://o6xux43a6gs4eidym2svvhon-wpengine.netdna-ssl.com/wp-content/uploads/sites/12/2018/02/Cardiac-Rhythm-News-issue-39-low-res.pdf
  Respicardia, Inc., a medical technology company developing therapies that improve cardiovascular health, have announced the first U.S. commercial case using the remedē system to treat central sleep apnoea was completed at The Ohio State University Wexner Medical Center in...
Natalia Trayanova envisions the future of cardiology and electrophysiology advancing through personalised medicine and computational simulations. Trayanova is the director of the Computational Cardiology Lab at Johns Hopkins University (Baltimore, USA), as well as the Murray B Sachs professor...
Local activation mapping at sites of termination of persistent atrial fibrillations (AF) shows repetitive patterns including rotational or focal activity reports a study in Circulation: Arrhythmia and Electrophysiology1. Therapy for persistent atrial fibrillation is limited by uncertainty about sustaining mechanisms. ...
The results of the CASTLE-AF study, published today in the New England Journal of Medicine, show that patients treated with radiofrequency catheter ablation rather than traditional drug therapies for atrial fibrillation had improved outcomes. “This clinical trial is the first time...
Following EHRA’s decision to hold its own annual congress in March and the difficulty for the industry to financially support Cardiostim as well as before, the decision has been taken no to hold Cardiostim 2018. In spite of the extraordinary...
  Boston Scientific Corporation today announced it has closed an investment and entered into an acquisition option agreement with Millipede, Inc., a privately-held company that has developed the  ring system for the treatment of severe mitral regurgitation (MR). Under the terms of the...
The results of ABRIDGE-J, a Japanese multicentre randomised study on minimally interrupted dabigatran vs. uninterrupted warfarin for catheter ablation, were presented during a late-breaking trials session at the American Heart Association (AHA) Scientific Sessions (11–15 November 2017, Anaheim, USA)....
Imricor Medical Systems announced today the completion of enrolment for the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter under real-time magnetic resonance imaging (MRI) guidance. The single-centre study enrolled 35 patients and was...
In October 2017, the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) released a guideline document on the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (SCD): a guideline document for healthcare professionals....
Vital USA Inc., a healthcare internet-of-things (IoT) vital sign company announced at the Consumer Technology Association's annual meeting (CES; 9-12 January, Las Vegas, USA) the release of the Vital Moto Mod: mobile monitoring platform featuring the first fully integrated platform to measure...
The US Food and Drug Administration (FDA) is providing information and recommendations regarding the Zoll LifeVest 4000 due to concerns that the device may fail to deliver treatment to the patient if the device is not replaced soon after...
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive safety and efficacy profile of Xarelto (rivaroxaban) established in the phase III ROCKET AF clinical trials,...
  Nearly a quarter of patients with chronic ischaemic cardiovascular disease are dead or hospitalised within six months, reports a European Society of Cardiology (ESC) study published in the European Journal of Preventive Cardiology.1 The Chronic Ischaemic Cardiovascular Disease (CICD) pilot registry...
  The cardiovascular magnetic resonance (CMR) 2018 meeting organised by European Association of Cardiovascular Imaging and the Society for Cardiovascular Magnetic Resonance will showcase the latest advances in CMR, and how they are improving patient care and outcomes. CMR 2018 will...
iMedrix, a Silicon Valley and Bangalore-based mHealth start up company, has announced the general availability of its product KardioScreen, a CE certified mobile and portable hospital-grade digital electrocardiogram (ECG). The system uses connected technology, bringing a “deep internet-of-things (IoT) architecture...
A study on substernal pacing acute clinical evaluation (SPACE) by Darius Sholevar (Our Lady of Lourdes Medical Center, Camden, USA) et al published in the Heart Rhythm journal has investigated the feasibility of extravascular pacing using a novel substernal electrode...
Abbott has announced the US Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labelling for the Quadra Assura MP cardiac resynchronisation therapy defibrillator (CRT-D) and Fortify Assura implantable cardioverter defibrillator (ICD), two of the company's most widely-used...
NightBalance, a Netherlands-based company developing obstructive sleep apnoea (OSA) therapies, has announced that the Dutch National Health Care Institute (ZIN) issued a positive recommendation to include its sleep apnoea therapy for reimbursement. The recommendation was issued to the Sleep...
This video has been sponsored by Abbott. The Confirm Rx implantable cardiac monitor (ICM) is the world’s first and only insertable cardiac monitor that combines a quick and minimally invasive procedure with Bluetooth wireless technology, allowing patients to connect using...
A recent study by Lu-Chen Weng (Massachusetts General Hospital, Boston, USA) et al which aimed to quantify and systematically characterise the genetic architecture of atrial fibrillation (AF) has found that genetic variation contributes substantially to AF susceptibility and risk. The...
The Optimizer system developed by Impulse Dynamics has received approval from the China Food and Drug Administration (CFDA). The Optimizer is an implantable cardiac contractility modulation therapy device for chronic heart failure patients. It is the only device therapy...
A retrospective national Swedish registry study by Leif Friberg and Mårten Rosenqvist (Karolinska Institutet, Stockholm, Sweden) has found that the risk of dementia is higher in atrial fibrillation (AF) patients without oral anticoagulant (OAC) treatment. The paper was presented...
The Heart Rhythm Society (HRS), in partnership with WebMD Education, has announced the launch of a free online educational tool for atrial fibrillation (AF). The new interactive AF information tool is part of a larger series of educational activities hosted by WebMD Education to help patients,...
A cluster analysis of the data from the ORBIT-AF observational registry study has been published by Taku Inohara (Duke University Medical Center, Durham, USA) et al in the Journal of the American Medical Association (JAMA). The cluster analysis of...
A small study by Phillip S Cuculich (Washington University School of Medicine, St Louis, USA) et al has shown that  radiation therapy, commonly used to treat cancer, can be used as a noninvasive radioablation approach to treat patients with...
Janssen has submitted a supplemental new drug application to the US FDA for two new indications for rivaroxaban (Xarelto, which is marketed by Bayer in Europe): reducing the risk of major cardiovascular events such as cardiac death, myocardial infarction or...
AliveCor has announced the issuance of a US patent which covers the use of data collected from wearable devices as a means of assisting diagnoses of cardiac arrhythmias, including those that may be asymptomatic. US Patent Number 9,839,363, entitled "Discordance...
Apple has launched the Apple Heart Study app, a first-of-its-kind research study using Apple Watch’s heart rate sensor to collect data on irregular heart rhythms and notify users who may be experiencing atrial fibrillation (AF). To calculate heart rate and rhythm, the...
Imricor is developing a magnetic resonance (MR) compatible injection catheter and has announced a joint development agreement with MiRTLE Medical to integrate MiRTLE’s MR compatible 12-lead ECG system with Imricor’s Advantage-MR EP Recorder/Stimulator System. This integration, along with Imricor’s MR...
Following a priority review by US Food and Drug Administration (FDA), evolocumab has received FDA approval in the USA. The drug is a PCSK9 inhibitor for reducing risk of myocardial infarction (MI), stroke and coronary revascularisation.   Pharmaceutical company Amgen has...
AliveCor has added another personal electrocardiogram (ECG) technology product to their range, announcing the US Food and Drug Administration (FDA) have cleared the Kardia Band in the USA. The Kardia Band works exclusively with the Apple Watch, providing owners of...
The Journal of the American Medical Association (JAMA) have published new guidelines on diagnostic testing for obstructive sleep apnoea (OSA) in adults. The new guidelines, authored by Babak Mokhlesi and Adam S. Cifu at the University of Chicago, USA, include updated...
NeuroproteXeon has announced the publication of a second finding from a randomised, controlled phase II trial of inhaled xenon and oxygen combined with hypothermia for out-of-hospital cardiac arrest patients. The study, which appeared in the Journal of the American...
EBR Systems has raised US$50 million to conduct the global SOLVE-CRT (stimulation of the left ventricle endocardially) study. SOLVE-CRT is a pivotal clinical trial intended to establish safety and efficacy in support of US Food and Drug Administration (FDA) approval WiSE (wireless stimulation endocardially), a product...
Acute myocardial infarction (MI) and stroke patients without medical insurance in the USA face “devastating” and catastrophic health expenses that can bankrupt them, new research shows. The study by Rohan Khera (University of Texas Southwestern Medical Centre, Dallas, USA)...
LivaNova has entered a binding letter of intent for the sale of its cardiac rhythm management business franchise to Shanghai-based company MicroPort for $190 million in cash. The companies, which have previously worked together in a joint venture, recently...
1. The "ILL-CONCEIVED" pallas study may be relaunched John Camm "I want to say just a few quick words about dronedarone", John Camm (St George's University of London and Imperial College, London, UK) told the audience of his talk at the Europe...
  A study published in the Circulation journal has shown that the risk of atrial fibrillation (AF) in young adults and children who suffer from congenital heart disease (CHD) was 22 times higher than in a matched control group. The study...
A new comparative study between dabigatran and warfarin finds similar ischemic stroke risks, but fewer brain bleeds for dabigatron compared with warfarin in US-based national drug surveillance network. More research is needed however, to determine whether dabigatran is associated...
Boehringer Ingelheim has announced results from two new analyses of the phase III RE-VERSE AD study, which evaluated the safety and efficacy of idarucizumab, marketed in the USA as Praxbind, in reversing the anticoagulant effect of Pradaxa (dabigatran etexilate...
Rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily also significantly (p=0.0003) reduces the risk of the composite outcome of major cardiovascular events, major adverse limb events and major amputation in patients with peripheral artery...
Presenters at the American Heart Association (AHA)’s annual Scientific Sessions (11-15 November 2017; Anaheim, USA) have identified the lack of awareness of automated external defibrillators (AEDs) in Latinos, as well as a general reluctance in bystanders to perform CPR...
Aziyo Biologics has announced the launch of their CanGaroo bio envelope specifically for use with subcutaneous implantable cardioverter-defibrillators (S-ICDs). It is the only cardiac implantable electronic device (CIED) envelope available for use with S-ICDs. CanGaroo is a natural extracellular matrix (ECM)...